

# Stephen L Chan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1915821/stephen-l-chan-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212  
papers

11,708  
citations

51  
h-index

106  
g-index

261  
ext. papers

15,673  
ext. citations

5.8  
avg. IF

6.24  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 212 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 379-379   | 2.2  | 36        |
| 211 | Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. <i>Cancer Letters</i> , <b>2022</b> , 525, 115-130   | 9.9  | 2         |
| 210 | CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein.. <i>Molecular Cancer</i> , <b>2022</b> , 21, 10  | 42.1 | 0         |
| 209 | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 1-12                                 | 7.5  | 1         |
| 208 | Immune Checkpoint Inhibitor-induced Enterocolitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, e70   | 6.9  |           |
| 207 | Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥10cm) in Tumour Response and Long-Term Survival Outcome. <i>CardioVascular and Interventional Radiology</i> , <b>2021</b> , 1         | 2.7  | 1         |
| 206 | Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". <i>Journal of Hepatology</i> , <b>2021</b> ,   | 13.4 | 1         |
| 205 | Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. <i>ELife</i> , <b>2021</b> , 10,   | 8.9  | 3         |
| 204 | Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. <i>JHEP Reports</i> , <b>2021</b> , 3, 100224   | 10.3 | 1         |
| 203 | A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , <b>2021</b> , 13,   | 17.5 | 11        |
| 202 | A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1375-1382   | 4.3  | 6         |
| 201 | Management of Gastrointestinal Side Effects of Immune Checkpoint Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2262-2265   | 6.9  | 0         |
| 200 | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , <b>2021</b> , 127, 865-874                                   | 6.4  | 8         |
| 199 | Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , <b>2021</b> , 3, 100215   | 10.3 | 10        |
| 198 | Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 1005-1015  | 15.4 | 7         |
| 197 | Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1274-1283  | 0.7  | 7         |
| 196 | Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , <b>2021</b> , 10, 107-114 | 9.1  | 15        |

|     |  |      |    |
|-----|--|------|----|
| 195 | ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211039928 <sup>5.4</sup>   | 5.4  | 2  |
| 194 | Dystrophin-negative slow-twitch soleus muscles are not susceptible to eccentric contraction induced injury over the lifespan of the mouse. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 321, C704-C720  | 5.4  | 3  |
| 193 | Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1492-1502  | 5.5  | 2  |
| 192 | Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 960-974   | 13.4 | 49 |
| 191 | Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , <b>2021</b> , 26, 39-52   | 3.7  | 2  |
| 190 | Genome-wide detection of cytosine methylation by single molecule real-time sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,   | 11.5 | 13 |
| 189 | Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 272-272 | 2.2  | 0  |
| 188 | Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2021</b> , 10, 510-521   | 9.1  | 7  |
| 187 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , <b>2020</b> , 9, 245-260  | 9.1  | 63 |
| 186 | Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , <b>2020</b> ,  | 13.3 | 1  |
| 185 | Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 867-875   | 0.7  | 13 |
| 184 | Microbiome and cancer treatment: Are we ready to apply in clinics?. <i>Progress in Molecular Biology and Translational Science</i> , <b>2020</b> , 171, 301-308  | 4    | 4  |
| 183 | Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). <i>Hpb</i> , <b>2020</b> , 22, 1121-1127  | 3.8  | 17 |
| 182 | Contaminated and misidentified cell lines commonly use in cancer research. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 573-574   | 5    | 4  |
| 181 | CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. <i>Cancer Research</i> , <b>2020</b> , 80, 2138-2149  | 10.1 | 56 |
| 180 | Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , <b>2020</b> , 477, 1-9   | 9.9  | 9  |
| 179 | Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2192-2201  | 4    | 1  |
| 178 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4795-4804   | 12.9 | 25 |

|     |  |      |     |
|-----|--|------|-----|
| 177 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 307-319   | 13.4 | 133 |
| 176 | Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 320-341   | 13.4 | 68  |
| 175 | Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 518-518  | 2.2  | 13  |
| 174 | RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 528-528  | 2.2  | 1   |
| 173 | Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 522-522 | 2.2  |     |
| 172 | Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , <b>2020</b> , 72, 198-212   | 11.2 | 47  |
| 171 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 193-202   | 2.2  | 600 |
| 170 | Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2020</b> , 9, 167-181   | 9.1  | 16  |
| 169 | Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 1461-1471  | 3.7  | 26  |
| 168 | Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. <i>Liver Cancer</i> , <b>2020</b> , 9, 491-502  | 9.1  | 26  |
| 167 | Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 7052-7061  | 4.8  | 5   |
| 166 | Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 10705-10713   | 5.6  | 2   |
| 165 | Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , <b>2020</b> , 30, 1144-1153   | 9.7  | 23  |
| 164 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , <b>2020</b> , 5,  | 6    | 21  |
| 163 | Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , <b>2020</b> , 2, 100152  | 10.3 | 8   |
| 162 | Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , <b>2020</b> , 69, 365-379  | 19.2 | 63  |
| 161 | Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , <b>2019</b> , 157, 1630-1645.e6  | 13.3 | 69  |
| 160 | A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , <b>2019</b> , 32, 1646-1656  | 9.8  | 11  |

|     |  |      |     |
|-----|--|------|-----|
| 159 | Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. <i>Nutrition and Cancer</i> , <b>2019</b> , 71, 954-970   | 2.8  | 5   |
| 158 | Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. <i>Quality of Life Research</i> , <b>2019</b> , 28, 2597-2607   | 3.7  | 3   |
| 157 | The association of liver function and quality of life of patients with liver cancer. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 66  | 3    | 11  |
| 156 | The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2019</b> , 457, 98-109                                      | 8.9  | 17  |
| 155 | Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mBI in patients with hepatocellular carcinoma. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 2719-2727  | 3.6  | 7   |
| 154 | Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2019</b> , 79, 1305-1317  | 10.1 | 19  |
| 153 | Systemic treatment of pancreatic neuroendocrine tumors. <i>Surgical Practice</i> , <b>2019</b> , 23, 48-58   | 0.4  |     |
| 152 | Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , <b>2019</b> , 29, 418-427   | 9.7  | 81  |
| 151 | Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , <b>2019</b> , 39, 2214-2229  | 7.9  | 116 |
| 150 | Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. <i>Annals of Oncology</i> , <b>2019</b> , 30, iv135-iv136  | 10.3 | 5   |
| 149 | Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1037-1048                               | 6.1  | 27  |
| 148 | Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4004-4004                 | 2.2  | 118 |
| 147 | Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4088-4088 | 2.2  | 12  |
| 146 | Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 423-423          | 2.2  | 5   |
| 145 | A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919889001                        | 5.1  | 24  |
| 144 | First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1696-1707   | 24.4 | 85  |
| 143 | Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2018</b> , 7, 40-54   | 9.1  | 16  |
| 142 | Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. <i>Hpb</i> , <b>2018</b> , 20, 546-554                     | 3.8  | 24  |

|     |   |      |      |
|-----|---|------|------|
| 141 | Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. <i>Radiology</i> , <b>2018</b> , 287, 340-348   | 20.5 | 4    |
| 140 | Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. <i>Theranostics</i> , <b>2018</b> , 8, 1740-1751  | 12.1 | 51   |
| 139 | Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1436-1445   | 5.7  | 4    |
| 138 | Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4020-4020   | 2.2  | 5    |
| 137 | Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4088-4088 | 2.2  | 6    |
| 136 | A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4144-TPS4144                     | 2.2  | 55   |
| 135 | Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 207-207                     | 2.2  | 51   |
| 134 | KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 209-209   | 2.2  | 20   |
| 133 | Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery. <i>Frontiers in Genetics</i> , <b>2018</b> , 9, 682  | 4.5  | 18   |
| 132 | Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 248-257   | 8.7  | 46   |
| 131 | Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , <b>2018</b> , 16, 163-170                                  | 2.5  | 17   |
| 130 | Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 89   | 5.2  | 20   |
| 129 | Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2018</b> , 17, 524-530  | 2.1  | 3    |
| 128 | Reply to Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma". <i>British Journal of Cancer</i> , <b>2018</b> , 119, 781-782  | 8.7  |      |
| 127 | ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 852   | 9.8  | 10   |
| 126 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 940-952  | 21.7 | 1120 |
| 125 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 54-63  | 59.2 | 1015 |
| 124 | Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 221-228   | 4    | 39   |



|     |  |      |     |
|-----|--|------|-----|
| 123 | Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 441-447  | 8.7  | 32  |
| 122 | Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , <b>2017</b> , 17, 8                   | 4.8  | 25  |
| 121 | Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 448-454  | 8.7  | 46  |
| 120 | Validating the ALBI grade: Its current and future use in HCC prognostication. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 661-663   | 13.4 | 6   |
| 119 | Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S620-S621   | 13.4 | 1   |
| 118 | Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 513-522   | 59.2 | 338 |
| 117 | A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , <b>2017</b> , 123, 3977-3985           | 6.4  | 13  |
| 116 | Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 280-289   | 7.9  | 28  |
| 115 | Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 506-514                            | 4    | 26  |
| 114 | Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression <b>2017</b> ,  |      | 12  |
| 113 | Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4143-TPS4143 | 2.2  | 3   |
| 112 | A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 262-262  | 2.2  | 1   |
| 111 | KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS503-TPS503                   | 2.2  | 24  |
| 110 | KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS504-TPS504                                       | 2.2  | 7   |
| 109 | Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , <b>2017</b> , 623-635               |      | 2   |
| 108 | Epidemiology of lung cancer: A joinpoint analysis of temporal incidence and mortality trends in 38 countries.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e13091-e13091   | 2.2  |     |
| 107 | A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15679-e15679  | 2.2  |     |
| 106 | Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , <b>2016</b> , 69, 971-984   | 7.3  | 15  |

|     |  |      |     |
|-----|--|------|-----|
| 105 | What do oncologists need to know about biosimilar products?. <i>Chinese Journal of Cancer</i> , <b>2016</b> , 35, 91   |      | 9   |
| 104 | Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1766-1772                    | 4    | 39  |
| 103 | Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 289-95  | 13.4 | 73  |
| 102 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , <b>2016</b> , 64, 774-84   | 11.2 | 58  |
| 101 | Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1300-6                      | 4    | 83  |
| 100 | Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , <b>2016</b> , 27, 639-49                                      | 2.4  | 6   |
| 99  | Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 83-90   | 2.2  | 105 |
| 98  | Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 45, 77-86  | 14.4 | 45  |
| 97  | The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3566-3566  | 2.2  | 1   |
| 96  | A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4074-4074 <sup>4</sup> |      |     |
| 95  | Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS3103-TPS3103 <sup>3</sup>       |      | 5   |
| 94  | Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , <b>2016</b> , 1-13                            |      |     |
| 93  | Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 7289-300   | 5.6  | 96  |
| 92  | Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi241  | 10.3 | 3   |
| 91  | Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 744-50   | 8.7  | 119 |
| 90  | Hepatotoxicity of targeted therapy for cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 789-802   | 5.5  | 10  |
| 89  | Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 875-886.e6                             | 6.9  | 141 |
| 88  | Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients". <i>European Journal of Cancer</i> , <b>2016</b> , 68, 203-205   | 7.5  |     |



|    |   |      |      |
|----|---|------|------|
| 87 | Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 550-8   | 2.2  | 1097 |
| 86 | Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 4138-48  | 3.1  | 162  |
| 85 | Hong Kong consensus recommendations on the management of hepatocellular carcinoma. <i>Liver Cancer</i> , <b>2015</b> , 4, 51-69   | 9.1  | 35   |
| 84 | Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 973-83  | 6.4  | 8    |
| 83 | Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 304-12   | 6.7  | 46   |
| 82 | A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , <b>2015</b> , 47, 178-81.6  |      | 9    |
| 81 | Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E5503-12 | 11.5 | 391  |
| 80 | Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 2720-9   | 6.4  | 34   |
| 79 | Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1529-35  | 4    | 13   |
| 78 | Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , <b>2015</b> , 2015, 564057   | 3.2  | 62   |
| 77 | Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma. <i>Current Gene Therapy</i> , <b>2015</b> , 15, 97-108   | 4.3  | 5    |
| 76 | Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , <b>2015</b> , 15, 395   | 4.8  | 72   |
| 75 | Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1224-35  | 6.1  | 57   |
| 74 | Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2457-63   | 10.3 | 62   |
| 73 | Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. <i>EBioMedicine</i> , <b>2015</b> , 2, 497-8   | 8.8  |      |
| 72 | Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1317-25   | 11.5 | 392  |
| 71 | A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6031-6031  | 2.2  | 2    |
| 70 | Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 237-237   | 2.2  | 4    |

|    |   |      |     |
|----|---|------|-----|
| 69 | A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4073-4073         | 2.2  |     |
| 68 | Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. <i>Histopathology</i> , <b>2014</b> , 64, 935-50   | 7.3  | 59  |
| 67 | Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. <i>Oncologist</i> , <b>2014</b> , 19, 1115-7  | 5.7  | 7   |
| 66 | Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. <i>Radiology</i> , <b>2014</b> , 270, 607-20  | 20.5 | 31  |
| 65 | Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2014</b> , 10, 80-91                      | 1.9  | 14  |
| 64 | Performance of serum $\alpha$ -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. <i>Hpb</i> , <b>2014</b> , 16, 366-72   | 3.8  | 39  |
| 63 | A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. <i>Cancer Research</i> , <b>2014</b> , 74, 6236-47   | 10.1 | 76  |
| 62 | An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 1607-14  | 5.5  | 8   |
| 61 | Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4094-4094   | 2.2  | 1   |
| 60 | Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4102-4102 | 2.2  | 13  |
| 59 | Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6029-6029        | 2.2  | 1   |
| 58 | Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3135-45  | 5.6  | 12  |
| 57 | Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. <i>Chinese Journal of Cancer</i> , <b>2014</b> , 33, 267-76   |      | 14  |
| 56 | International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , <b>2014</b> , 33, 481-91  |      | 18  |
| 55 | A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 181-181                                    | 2.2  |     |
| 54 | Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1417-25  | 3.5  | 12  |
| 53 | Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. <i>Gastroenterology</i> , <b>2013</b> , 144, 1086-1097.e9   | 13.3 | 52  |
| 52 | Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 211-24                                     | 5.5  | 373 |

|    |   |      |     |
|----|---|------|-----|
| 51 | Re: roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 580   | 9.7  |     |
| 50 | Targeted therapy for hepatocellular carcinoma: current status and future direction. <i>Clinical Investigation</i> , <b>2013</b> , 3, 83-93  |      |     |
| 49 | Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. <i>Cancer Research</i> , <b>2013</b> , 73, 1676-88   | 10.1 | 127 |
| 48 | Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18761-8  | 11.5 | 267 |
| 47 | Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , <b>2013</b> , 2013, 103830   | 2.7  | 16  |
| 46 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. <i>Cancer</i> , <b>2013</b> , 119, 4145-53  | 6.4  | 9   |
| 45 | Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 425-425 | 2.2  |     |
| 44 | Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. <i>Hong Kong Medical Journal</i> , <b>2013</b> , 19, 407-15   | 0.7  | 3   |
| 43 | Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , <b>2012</b> , 83, 1146-58  | 6    | 20  |
| 42 | Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 74-5; discussion 75   | 6.1  | 1   |
| 41 | Targeted therapy of hepatocellular carcinoma: present and future. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 862-72  | 4    | 63  |
| 40 | Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 300-4  | 5.3  | 68  |
| 39 | Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3361-7                    | 2.2  | 146 |
| 38 | Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16 Suppl 1, S63-8   | 6.4  | 18  |
| 37 | A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 3984-92   | 6.4  | 43  |
| 36 | Management of hepatocellular carcinoma: beyond sorafenib. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 257-66.3  |      | 22  |
| 35 | Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 271-8   | 7.9  | 14  |
| 34 | A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1287-1292  | 10.3 | 91  |

|    |   |      |     |
|----|---|------|-----|
| 33 | A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14528-e14528                                       | 2.2  |     |
| 32 | 6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma [a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)]. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S470-S471 | 7.5  | 3   |
| 31 | Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 340-7  | 4    | 64  |
| 30 | PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 539-45  | 3.5  | 26  |
| 29 | Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1280-1287   | 10.3 | 77  |
| 28 | A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2592-2592  | 2.2  | 2   |
| 27 | The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 205-205  | 2.2  | 1   |
| 26 | Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. <i>Hong Kong Medical Journal</i> , <b>2011</b> , 17, 112-8  | 0.7  | 10  |
| 25 | Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1660-5   | 2.2  | 336 |
| 24 | Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. <i>Contemporary Clinical Trials</i> , <b>2010</b> , 31, 135  | 2.3  | 1   |
| 23 | PARP inhibition in BRCA-mutated breast and ovarian cancers. <i>Lancet, The</i> , <b>2010</b> , 376, 211-3   | 4.0  | 38  |
| 22 | The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 107-14   | 4.3  | 52  |
| 21 | A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2010</b> , 878, 2409-14                        | 3.2  | 7   |
| 20 | Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2585-2585  | 2.2  | 2   |
| 19 | Reply to L.-T. Chen et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e272-e272  | 2.2  | 1   |
| 18 | New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 446-52  | 2.2  | 205 |
| 17 | Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1854-9  | 10.3 | 47  |
| 16 | TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 644-52   | 7.5  | 143 |

|    |   |      |     |
|----|---|------|-----|
| 15 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 529-35  | 4.4  | 65  |
| 14 | Lymphedema and quality of life in Chinese women after treatment for breast cancer. <i>European Journal of Oncology Nursing</i> , <b>2009</b> , 13, 110-5  | 2.8  | 36  |
| 13 | Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , <b>2009</b> , 5, 889-99   | 3.6  | 26  |
| 12 | High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 177-82   | 2.2  | 242 |
| 11 | Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3052-3052   | 2.2  | 2   |
| 10 | A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 6055-6055 | 2.2  | 10  |
| 9  | Accomplishments in 2007 in the management of hepatobiliary cancers. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2008</b> , 2, S25-31  |      | 5   |
| 8  | Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , <b>2007</b> , 45, 1382-9   | 11.2 | 55  |
| 7  | The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. <i>Laboratory Investigation</i> , <b>2007</b> , 87, 644-50   | 5.9  | 84  |
| 6  | Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , <b>2006</b> , 6, 259   | 4.8  | 6   |
| 5  | Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1083-9  | 10.3 | 85  |
| 4  | An unusual cause of superior vena cava obstruction. <i>Thorax</i> , <b>2006</b> , 61, 182   | 7.3  | 3   |
| 3  | Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta Oncologica</i> , <b>2005</b> , 44, 177-9  | 3.2  | 2   |
| 2  | Misleading chest radiography in a patient with SARS. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2004</b> , 36, 318-20  |      | 0   |
| 1  | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma   |      | 12  |